Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
31 January 1997Website:
http://www.cerus.comNext earnings report:
01 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 9 min agoDividend
Analysts recommendations
Institutional Ownership
CERS Latest News
Cerus (CERS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.07 per share a year ago.
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38th International Congress of the International Society of Blood Transfusion (ISBT), taking place in Barcelona, Spain, from June 23 through June 27. Transfusion medicine experts and professionals from around the world attend the ISBT Congress. The following is a list of selected presentations and abstracts of interest for Cerus. All presentation times are listed.
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2024. In 2005, the World Health Assembly designated June 14 as World Blood Donor Day to recognize and thank blood donors across the world for their important contributions to the global blood supply. For 2024, the focus of this day is on all blood donors, essential for ensuring patients have access to blood transfusion, as well as on efforts to overcome challenges and.
Cerus Corporation (NASDAQ:CERS) will be hosting a conference call to discuss their Q1 2024 results on May 2, 2024 at 4:30 PM ET. The call will feature key company executives including Jessica Hanover, Obi Greenman, Vivek Jayaraman, Kevin Green, and Carol Moore. Analysts participating in the call include Emily Christy, Jacob Johnson, Ross Osborne, and William Bonello. The operator will begin the call shortly. Thank you for joining us.
Cerus Corporation (NASDAQ:CERS ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President & Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Conference Call Participants Operator Good day and thank you for standing by. Welcome to Cerus Corporation Second Quarter 2023 Earnings Conference Call.
Cerus (CERS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.05 per share a year ago.
Cerus (CERS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.05 per share a year ago.
While Most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the amount of shares they can buy.
Today, we put medical device concern Cerus Corporation in the spotlight. Cerus has some current challenges, which management believes are temporary. Sales growth is projected to accelerate significantly in FY2024.
Cerus (CERS) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.07 per share a year ago.
What type of business is Cerus?
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
What sector is Cerus in?
Cerus is in the Healthcare sector
What industry is Cerus in?
Cerus is in the Medical Devices industry
What country is Cerus from?
Cerus is headquartered in United States
When did Cerus go public?
Cerus initial public offering (IPO) was on 31 January 1997
What is Cerus website?
https://www.cerus.com
Is Cerus in the S&P 500?
No, Cerus is not included in the S&P 500 index
Is Cerus in the NASDAQ 100?
No, Cerus is not included in the NASDAQ 100 index
Is Cerus in the Dow Jones?
No, Cerus is not included in the Dow Jones index
When was Cerus the previous earnings report?
No data
When does Cerus earnings report?
The next expected earnings date for Cerus is 01 November 2024